Novel Biomarkers Improve Prediction of 365-Day Readmission After Pediatric Congenital Heart Surgery

• Published in: The Annals of thoracic surgery Vol. 109; no. 1; pp. 164 - 170
• Main Authors: Parker, Devin M., Everett, Allen D., Stabler, Meagan E., Vricella, Luca, Jacobs, Marshall L., Jacobs, Jeffrey P., Parikh, Chirag R., Pasquali, Sara K., Brown, Jeremiah R.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 01-01-2020
• Subjects: Biomarkers - blood; Cardiac Surgical Procedures; Child; Child, Preschool; Female; Galectin 3 - blood; Glial Fibrillary Acidic Protein - blood; Heart Defects, Congenital - blood; Heart Defects, Congenital - mortality; Heart Defects, Congenital - surgery; Humans; Infant; Infant, Newborn; Interleukin-1 Receptor-Like 1 Protein - blood; Male; Natriuretic Peptide, Brain - blood; Patient Readmission - statistics & numerical data; Predictive Value of Tests; Prospective Studies; Time Factors; STAT; NT-proBNP; OR; STS; CI; AUROC; CHSD; GFAP
• ISSN: 0003-4975; 1552-6259
• DOI: 10.1016/j.athoracsur.2019.05.070

The purpose of this study was to evaluate the association between preoperative biomarker levels and 365-day readmission or mortality after pediatric congenital heart surgery.
Children aged 18 years or younger undergoing congenital heart surgery (n = 145) at Johns Hopkins Hospital from 2010 to 2014 were enrolled in the prospective cohort. Novel biomarkers suppression of tumorgenicity 2, galectin-3, N-terminal prohormone brain natriuretic peptide, and glial fibrillary acidic protein were measured. The composite study endpoint was unplanned readmission within 365 days after discharge or mortality either in hospital during the surgical admission or within 365 days after discharge. A clinical model based on covariates used in The Society of Thoracic Surgeons Congenital Heart Surgery Database mortality risk model and an augmented model using the clinical model in conjunction with a novel biomarker panel were evaluated.
Readmission or mortality within 365 days of surgery occurred among 39 pediatric patients (27%). The clinical model alone resulted in a c-statistic of 0.719 (95% confidence interval, 0.63 to 0.81). The clinical model in conjunction with the log-transformed biomarkers improved the c-statistic to 0.805 (95% confidence interval, 0.73 to 0.88). The addition of biomarkers resulted in a significant improvement to the clinical model alone (P value = 0.035).
Novel biomarkers may add predictive value when assessing the likelihood of 365-day readmission or mortality after pediatric congenital heart surgery. After adjusting for clinical and novel biomarkers, preoperative and postoperative suppression of tumorgenicity 2 remained associated with 365-day readmission or mortality. Currently, The Society of Thoracic Surgeons clinical congenital mortality risk model can be applied to identify children with increased risk of repeat hospitalizations and postdischarge mortality and may inform preventative care interventions that aim to reduce these adverse events.